614 related articles for article (PubMed ID: 11712811)
1. Chemotherapy and concomitant irradiation in inflammatory breast cancer.
Tubiana-Mathieu N; Lejeune C; Bonnier P; Genet D; Adjadj DJ; Berda JF; Muracciole X; Delaby F; Clavere P; Benyoub A; Rhein B; Juin B; Piana L
Anticancer Res; 2001; 21(4B):3061-7. PubMed ID: 11712811
[TBL] [Abstract][Full Text] [Related]
2. Concomitant intensive chemoradiotherapy induction in non-metastatic inflammatory breast cancer: long-term follow-up.
Genet D; Lejeune C; Bonnier P; Aubard Y; Venat-Bouvet L; Adjadj DJ; Martin J; Labourey JL; Benyoub A; Clavère P; Lebrun-Ly V; Juin P; Piana L; Tubiana-Mathieu N
Br J Cancer; 2007 Oct; 97(7):883-7. PubMed ID: 17876327
[TBL] [Abstract][Full Text] [Related]
3. Exclusive alternating chemotherapy and radiotherapy in nonmetastatic inflammatory breast cancer: 20 years of follow-up.
Bourgier C; Pessoa EL; Dunant A; Heymann S; Spielmann M; Uzan C; Mathieu MC; Arriagada R; Marsiglia H
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):690-5. PubMed ID: 21277101
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial.
Veyret C; Levy C; Chollet P; Merrouche Y; Roche H; Kerbrat P; Fumoleau P; Fargeot P; Clavere P; Chevallier B
Cancer; 2006 Dec; 107(11):2535-44. PubMed ID: 17054108
[TBL] [Abstract][Full Text] [Related]
5. [High-dose CEF (cyclophosphamide, epirubicin, fluorouracil) as primary chemotherapy in locally advanced breast cancer: long-term results].
Conti F; Carpano S; Sergi D; Di Lauro L; Amodio A; Vici P; Abbate MI; Ferranti FR; Viola G; Botti C; Foggi P; Sperduti I; Lopez M
Clin Ter; 2007; 158(4):331-41. PubMed ID: 17953285
[TBL] [Abstract][Full Text] [Related]
6. [Locally advanced non inflammatory breast cancer treated by combined chemotherapy and preoperative irradiation: updated results in a series of 120 patients].
Lerouge D; Touboul E; Lefranc JP; Genestie C; Moureau-Zabotto L; Blondon J
Cancer Radiother; 2004 Jun; 8(3):155-67. PubMed ID: 15217583
[TBL] [Abstract][Full Text] [Related]
7. First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial).
Viens P; Palangié T; Janvier M; Fabbro M; Roché H; Delozier T; Labat JP; Linassier C; Audhuy B; Feuilhade F; Costa B; Delva R; Cure H; Rousseau F; Guillot A; Mousseau M; Ferrero JM; Bardou VJ; Jacquemier J; Pouillart P
Br J Cancer; 1999 Oct; 81(3):449-56. PubMed ID: 10507769
[TBL] [Abstract][Full Text] [Related]
8. Multimodality treatment of 128 patients with locally advanced breast carcinoma in the era of mammography screening using standard polychemotherapy with 5-fluorouracil, epirubicin, and cyclophosphamide: prognostic and therapeutic implications.
Karlsson YA; Malmström PO; Hatschek T; Fornander TG; Söderberg M; Bengtsson NO; Jansson TE; Sjöberg SM; Bergh JC
Cancer; 1998 Sep; 83(5):936-47. PubMed ID: 9731898
[TBL] [Abstract][Full Text] [Related]
9. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
[TBL] [Abstract][Full Text] [Related]
10. Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm.
Calais G; Berger C; Descamps P; Chapet S; Reynaud-Bougnoux A; Body G; Bougnoux P; Lansac J; Le Floch O
Cancer; 1994 Aug; 74(4):1283-8. PubMed ID: 8055449
[TBL] [Abstract][Full Text] [Related]
11. Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy.
Gasparini G; Barbareschi M; Boracchi P; Verderio P; Caffo O; Meli S; Dalla Palma P; Marubini E; Bevilacqua P
Cancer J Sci Am; 1995; 1(2):131-41. PubMed ID: 9166466
[TBL] [Abstract][Full Text] [Related]
12. [Intensive chemotherapy in the treatment of patients with metastatic breast cancer].
Salgado JE; Aramendía JM; Fernández-Hidalgo OA; Lozano E; Rebollo J; Martínez-Monge R; Subirá ML; Brugarolas A
Rev Med Univ Navarra; 1997; 41(3):143-51. PubMed ID: 10420919
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes.
Battelli N; Massacesi C; Braconi C; Pilone A; Manzione L; Dinota A; Cobelli S; Scanni A; Sturba F; Giacomini G; Morale D; Giorgi F; Tummarello D; Cascinu S
Am J Clin Oncol; 2006 Aug; 29(4):380-4. PubMed ID: 16891866
[TBL] [Abstract][Full Text] [Related]
14. The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer.
De Placido S; Lauria R; Carlomagno C; Perrone F; De Laurentiis M; Gallo C; Martignetti A; Bellelli T; Limite G; Petrella G; Bianco AR
Int J Oncol; 1999 Aug; 15(2):339-46. PubMed ID: 10402245
[TBL] [Abstract][Full Text] [Related]
15. Multidisciplinary therapy of locally far-advanced or inflammatory breast cancer with fixed perioperative sequence of epirubicin, vinorelbine, and Fluorouracil chemotherapy, surgery, and radiotherapy: long-term results.
Ardavanis A; Scorilas A; Tryfonopoulos D; Orphanos G; Missitzis I; Karamouzis M; Chrysochoou M; Sotiropoulou A; Arnogiannaki N; Ioannidis G; Pissakas G; Rigatos G
Oncologist; 2006 Jun; 11(6):563-73. PubMed ID: 16794236
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
17. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
[TBL] [Abstract][Full Text] [Related]
18. Epirubicin versus mitoxantrone in combination chemotherapy for metastatic breast cancer.
Pavesi L; Preti P; Da Prada G; Pedrazzoli P; Poggi G; Robustelli della Cuna G
Anticancer Res; 1995; 15(2):495-501. PubMed ID: 7763029
[TBL] [Abstract][Full Text] [Related]
19. Extracapsular extension in positive axillary lymph nodes in female breast cancer patients. Patterns of failure and indications for postoperative locoregional irradiation.
Stranzl H; Mayer R; Ofner P; Peintinger F; Prettenhofer U; Hackl A
Strahlenther Onkol; 2004 Jan; 180(1):31-7. PubMed ID: 14704842
[TBL] [Abstract][Full Text] [Related]
20. [Dose intensified adjuvant chemotherapy in high risk breast carcinoma with 4-9 positive lymph nodes].
Elling D; Krocker J; Kümmel S; Blohmer J; Lichtenegger W; Kohls A; Heinrich J; Quass J; Breitbach P; Köhler U
Zentralbl Gynakol; 2000; 122(4):207-16. PubMed ID: 10795118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]